

Claim 90 (REITERATED).

The compound of claim 89, having the structure:



Claim 91 (REITERATED).

The compound of claim 74, wherein the N-terminus of the peptide is coupled to a polyethylene glycol molecule.

Claim 92 (REITERATED).

The compound of claim 74, wherein the N-terminus of the peptide is acetylated.

Claim 93 (REITERATED).

The compound of claim 74, wherein the C-terminus of the peptide is amidated.

REMARKS

Claims 74, 85-87 and 89-93 stand objected to.

Claim 74 has been amended. Claims 85-87 have been canceled. Claims 89-93 remain unchanged.

Applicants previously submitted an Amendment under 37 C.F.R. §1.111 in response to the Office Action mailed on March 28, 2002 ("Previous Amendment"). The Examiner, in the instant Office Communication, has asserted that Applicants' Previous Amendment was not fully responsive and further claim amendments have been requested. However, Applicants have prepared this response under the assumption that the Previous Amendment has been entered, and therefore, certain issues with regard to the Drawings and so forth will not be addressed here as Applicants believe such issues were fully responded to therein.

THE AMENDMENT

Claim 74 has been amended to recite the elected embodiment, SEQ ID NO:208.

Claims 85-87 have been canceled as they are directed to the non-elected embodiments of SEQ ID NO: 157-186 and 187-213.